Neos names chief commercial officer
This article was originally published in Scrip
Neos Therapeutics, a company developing a late-stage pipeline of innovative extended-release product candidates for the treatment of attention-deficit hyperactivity disorder, has appointed Thomas P McDonnell chief commercial officer – effective immediately. Prior to joining Neos, Mr McDonnell spent 10 years with Shire, most recently as vice-president of US marketing in the neuroscience business unit from December 2013 to March 2015. In this role, he led the US product strategy team responsible for the commercialization of Vyvanse and Intuniv into the ADHD market.